Valuation Matinas BioPharma Holdings, Inc.
Stocks
MTNB
US5768104029
Biotechnology & Medical Research
|
Market Closed -
NYSE
16:00:00 2026-11-02 EST
|
5-day change | 1st Jan Change | ||
| 1.290 USD | -14.57% |
|
-22.29% | -85.32% |
| 08-20 | Top Premarket Decliners | MT |
| 08-13 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Matinas BioPharma Holdings, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 271.5 | 218.4 | 108.4 | 46.97 | 2.594 | 3.754 |
| Change | - | -19.56% | -50.35% | -56.68% | -94.48% | 44.7% |
| Enterprise Value (EV) 1 | 216.6 | 173.5 | 83.79 | 36.77 | -1.796 | 1.109 |
| Change | - | -19.9% | -51.7% | -56.11% | -104.88% | 161.76% |
| P/E | -11.5x | -8.96x | -5.16x | -2.05x | -0.1x | -0.29x |
| PBR | 4.54x | 4.16x | 2.97x | 2.44x | 0.34x | 0.78x |
| PEG | - | 1.97x | 0.4x | -0.23x | 0.02x | 0x |
| Capitalization / Revenue | 1,715x | 6,552x | 34x | 42.9x | - | - |
| EV / Revenue | 1,368x | 5,205x | 26.3x | 33.6x | - | - |
| EV / EBITDA | -9.06x | -7.09x | -3.46x | -1.57x | 0.09x | -0.16x |
| EV / EBIT | -8.95x | -7.01x | -3.41x | -1.55x | 0.09x | -0.16x |
| EV / FCF | -22.2x | -21x | -5.82x | -5.37x | 0.24x | -0.33x |
| FCF Yield | -4.51% | -4.75% | -17.2% | -18.6% | 415% | -301% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -88.53 | -84.5 | -72.63 | -79.2 | -74.76 | -30.04 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.1583 | 0.0333 | 3.188 | 1.096 | - | - |
| EBITDA 1 | -23.92 | -24.45 | -24.23 | -23.37 | -19.79 | -6.924 |
| EBIT 1 | -24.21 | -24.73 | -24.59 | -23.77 | -20.16 | -6.96 |
| Net income 1 | -22.45 | -23.28 | -21 | -22.94 | -24.25 | -10.34 |
| Net Debt 1 | -54.93 | -44.92 | -24.64 | -10.2 | -4.39 | -2.645 |
| Reference price 2 | 1,020.000 | 757.500 | 375.000 | 162.150 | 7.650 | 8.790 |
| Nbr of stocks (in thousands) | 266 | 288 | 289 | 290 | 339 | 427 |
| Announcement Date | 3/29/21 | 3/8/22 | 3/15/23 | 3/27/24 | 4/15/25 | 3/31/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 1.48M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.86x | 0.86% | 54.62B | |
| 34.85x | 3.31x | 14.29x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -70.14x | 13.02x | -68.47x | -.--% | 24.7B | |
| Average | 17.50x | 28.01x | 7.09x | 0.34% | 39.43B | |
| Weighted average by Cap. | 21.73x | 26.34x | 11.23x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MTNB Stock
- Valuation Matinas BioPharma Holdings, Inc.
Select your edition
All financial news and data tailored to specific country editions
